Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breckenridge Pharmaceutical Inc.

Division of Towa Pharmaceutical Co. Ltd.
bpirx.com

Latest From Breckenridge Pharmaceutical Inc.

Towa Expands Internationally With Esteve’s Pensa

Japan’s Towa has struck a deal to acquire the Pensa Investments generics division of Spain’s Esteve in an all-cash transaction worth €320m. The acquisition gives Towa access to the Spanish market as well as subsidiaries in Europe and the US.

Deals Strategy

Older Patents Get Help As Federal Circuit Sides With Novartis In Gilenya, Everolimus Disputes

US court finds no obviousness-type double patenting under statute that changed patent term from 17 years from issuance to 20 years from filing; decisions will impact other cases involving patents issued prior to statute.

Generic Drugs Legal Issues

OTC-Only PEG Market Nears After Court Passes On Stopping Rx ANDA Withdrawals

US circuit court rejects petitions from Breckenridge Pharmaceutical, Lannett Co., Nexgen Pharma and Paddock Labs to order FDA to conduct a hearing on their requests to sustain approvals for Rx PEG 3350 generics. FDA's approvals of the Rx ANDAs are set to expire Nov. 2; the agency said the Rx products were rendered unapproved in 2006 when the same formulation became available OTC.

Gastrointestinal Health

OTC-Only PEG Market Nears After Court Passes On Stopping Rx ANDA Withdrawals

US circuit court rejects petitions from Breckenridge Pharmaceutical, Lannett Co., Nexgen Pharma and Paddock Labs to order FDA to conduct a hearing on their requests to sustain approvals for Rx PEG 3350 generics. FDA's approvals of the Rx ANDAs are set to expire Nov. 2; the agency said the Rx products were rendered unapproved in 2006 when the same formulation became available OTC.

Gastrointestinal Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Dermatology
  • Gastrointestinal
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Towa Pharmaceutical Co. Ltd.
  • Senior Management
  • Larry Runsdorf, Pres.
    Marty Schatz , VP, Sales
    Larry J Lapila, EVP, Bus. Dev.
    Todd Ruonavaara, VP, Fin.
  • Contact Info
  • Breckenridge Pharmaceutical Inc.
    Phone: (860) 828-8140
    15 Massirio Dr.
    Ste. 201
    Berlin, CT 06037
    USA
UsernamePublicRestriction

Register